Ken Solt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ken Solt has a total of 476 co-authors. Here are the top co-authors by number of shared publications:
- Emery N. Brown
Massachusetts Institute of Technology
12 shared publications Douglas E. Raines
11 shared publicationsEmery N. Brown
Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, BostonMA, United States
11 shared publications- Norman E. Taylor
Department of Anesthesiology, University of Utah, School of Medicine, Salt Lake City, UT, United States
11 shared publications Jessica J. Chemali
Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts
9 shared publications- Kathleen F. Vincent
Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA; Department of Anaesthesia, Harvard Medical School, Boston, MA, USA
8 shared publications
Latest Publications
- 23 October 2026
- Published by Wolters Kluwer Health in Anesthesiology
Role of Ventral Tegmental Area Dopamine Neurons in Emergence from Dexmedetomidine, Fentanyl, and Ketamine Anesthesia in Rats
Background: Dopamine neurons in the ventral tegmental area (VTA), a midbrain structure, have been widely implicated in promoting emergence from general anesthesia. However, most studies have focused on anesthetics that primarily target γ-aminobutyric acid type A receptors. Whether these neurons also facilitate emergence from mechanistically diverse drug-induced unconscious states is not known. This study examined the specific contribution of VTA dopamine neurons in restoring arousal after sevoflurane-, dexmedetomidine-, fentanyl-, and ketamine-induced unconsciousness. Methods: Adult Sprague Dawley rats received viral constructs driving selective expression in tyrosine hydroxylase–positive VTA neurons of either channelrhodopsin or the control protein, yellow fluorescent protein. Accurate targeting in VTA TH:ChR was confirmed by assessing righting in response to photostimulation during continuous sevoflurane inhalation (1.4 to 2.0%). In a randomized block design, the rats were exposed to dexmedetomidine (15 µg/kg IV bolus), fentanyl (50 µg/kg IV bolus), or ketamine (50 mg/kg IV infusion). After loss of the righting reflex, behavioral arousal and frontal electroencephalography activity were recorded with or without photostimulation. The proportion of animals righting during the light-on and light-off conditions was assessed in a mixed-effects Cox regression model, and spectral power differences were quantified with effect size estimates. Results: Optogenetic stimulation of VTA dopamine neurons during continuous sevoflurane inhalation restored righting in VTA TH:ChR rats, with a median latency of 4.7 min (95% CI, 2.6 to 6.4) after the onset of photostimulation. VTA TH:ChR rats were significantly more likely to right during photostimulation after dexmedetomidine (hazard ratio, 27.7; 95% CI, 2.7 to 287.1; P = 0.0053), and responders showed attenuated spectral power in low frequencies (less than 12 Hz) in VTA TH:ChR . Optogenetic stimulation did not affect behavioral nor neurophysiologic measures of arousal after fentanyl. Finally, optogenetic stimulation in VTA TH:ChR rats modestly delayed emergence from ketamine sedation without altering electroencephalography spectral power. Conclusions: These data suggest that the role of dopamine VTA neurons in anesthetic emergence is agent specific and likely shaped by distinct and sometimes opposing neural pathways.
- 23 October 2026
- Published by Wolters Kluwer Health in Anesthesiology
Role of Ventral Tegmental Area Dopamine Neurons in Emergence from Dexmedetomidine, Fentanyl, and Ketamine Anesthesia in Rats
Background: Dopamine neurons in the ventral tegmental area (VTA), a midbrain structure, have been widely implicated in promoting emergence from general anesthesia. However, most studies have focused on anesthetics that primarily target γ-aminobutyric acid type A receptors. Whether these neurons also facilitate emergence from mechanistically diverse drug-induced unconscious states is not known. This study examined the specific contribution of VTA dopamine neurons in restoring arousal after sevoflurane-, dexmedetomidine-, fentanyl-, and ketamine-induced unconsciousness. Methods: Adult Sprague Dawley rats received viral constructs driving selective expression in tyrosine hydroxylase–positive VTA neurons of either channelrhodopsin or the control protein, yellow fluorescent protein. Accurate targeting in VTA TH:ChR was confirmed by assessing righting in response to photostimulation during continuous sevoflurane inhalation (1.4 to 2.0%). In a randomized block design, the rats were exposed to dexmedetomidine (15 µg/kg IV bolus), fentanyl (50 µg/kg IV bolus), or ketamine (50 mg/kg IV infusion). After loss of the righting reflex, behavioral arousal and frontal electroencephalography activity were recorded with or without photostimulation. The proportion of animals righting during the light-on and light-off conditions was assessed in a mixed-effects Cox regression model, and spectral power differences were quantified with effect size estimates. Results: Optogenetic stimulation of VTA dopamine neurons during continuous sevoflurane inhalation restored righting in VTA TH:ChR rats, with a median latency of 4.7 min (95% CI, 2.6 to 6.4) after the onset of photostimulation. VTA TH:ChR rats were significantly more likely to right during photostimulation after dexmedetomidine (hazard ratio, 27.7; 95% CI, 2.7 to 287.1; P = 0.0053), and responders showed attenuated spectral power in low frequencies (less than 12 Hz) in VTA TH:ChR . Optogenetic stimulation did not affect behavioral nor neurophysiologic measures of arousal after fentanyl. Finally, optogenetic stimulation in VTA TH:ChR rats modestly delayed emergence from ketamine sedation without altering electroencephalography spectral power. Conclusions: These data suggest that the role of dopamine VTA neurons in anesthetic emergence is agent specific and likely shaped by distinct and sometimes opposing neural pathways.
- 1 October 2026
- Published by Wolters Kluwer Health in Anesthesiology
Assessment of Vigilance Recovery in Rats Following Anesthesia Using a Touchscreen-Based Continuous Performance Task
Background: Cognitive recovery following general anesthesia is clinically important but incompletely understood. Rodent studies in anesthesia research have primarily examined memory and learning, while vigilance and other neurocognitive domains remain underexplored. To address this gap, we employed the rodent Continuous Performance Task (rCPT), a touchscreen-based translational paradigm, to characterize anesthetic-specific recovery trajectories of vigilance following anesthetic emergence. Methods: Sixteen adult Sprague Dawley rats (8 male, 8 female) were trained to proficiency on the rCPT. Once trained, loss of righting was induced by sevoflurane (3% for 20 min), propofol (10 mg/kg i.v. bolus), ketamine (50 mg/kg i.v. over 10 min), or dexmedetomidine (20 µg/kg i.v. bolus), delivered in a randomized order every other week. Animals were placed supine in the cognitive testing chamber and their performance was recorded for four hours. Return of righting reflex (RORR) was used to indicate anesthetic emergence. Vigilance recovery was defined as 20 consecutive trials with an average hit rate >0.6. Results: The latency to recover vigilance was delayed following ketamine and dexmedetomidine compared to baseline (Hazard Ratio in ketamine, 5.34; 95% CI, 2.07, 13.76; Hazard Ratio in dexmedetomidine, 5.33; 95% CI, 2.08, 13.62; both p<.0001). Reward retrieval latency recovered 4 hours after RORR following ketamine (percent change from baseline, -24.14%; 95% CI, -54.69, 17.89%) but not recover at the same time point following dexmedetomidine (percent change from baseline, -47.85%; 95% CI, -71.94, -20.23%). Conclusions: The rCPT identified delayed recovery of vigilance following ketamine and dexmedetomidine. Dexmedetomidine showed prolonged impairment across behavioral measures, including visual processing speed (hit latency) and reward retrieval, suggesting sustained effects on psychomotor function, motor coordination, and behavioral engagement that persisted for at least 4 hours after RORR. These findings support the utility of the rCPT as a translational paradigm for characterizing agent-specific and domain-specific trajectories of cognitive recovery following anesthesia.
- 1 October 2026
- Published by Wolters Kluwer Health in Anesthesiology
Assessment of Vigilance Recovery in Rats Following Anesthesia Using a Touchscreen-Based Continuous Performance Task
Background: Cognitive recovery following general anesthesia is clinically important but incompletely understood. Rodent studies in anesthesia research have primarily examined memory and learning, while vigilance and other neurocognitive domains remain underexplored. To address this gap, we employed the rodent Continuous Performance Task (rCPT), a touchscreen-based translational paradigm, to characterize anesthetic-specific recovery trajectories of vigilance following anesthetic emergence. Methods: Sixteen adult Sprague Dawley rats (8 male, 8 female) were trained to proficiency on the rCPT. Once trained, loss of righting was induced by sevoflurane (3% for 20 min), propofol (10 mg/kg i.v. bolus), ketamine (50 mg/kg i.v. over 10 min), or dexmedetomidine (20 µg/kg i.v. bolus), delivered in a randomized order every other week. Animals were placed supine in the cognitive testing chamber and their performance was recorded for four hours. Return of righting reflex (RORR) was used to indicate anesthetic emergence. Vigilance recovery was defined as 20 consecutive trials with an average hit rate >0.6. Results: The latency to recover vigilance was delayed following ketamine and dexmedetomidine compared to baseline (Hazard Ratio in ketamine, 5.34; 95% CI, 2.07, 13.76; Hazard Ratio in dexmedetomidine, 5.33; 95% CI, 2.08, 13.62; both p<.0001). Reward retrieval latency recovered 4 hours after RORR following ketamine (percent change from baseline, -24.14%; 95% CI, -54.69, 17.89%) but not recover at the same time point following dexmedetomidine (percent change from baseline, -47.85%; 95% CI, -71.94, -20.23%). Conclusions: The rCPT identified delayed recovery of vigilance following ketamine and dexmedetomidine. Dexmedetomidine showed prolonged impairment across behavioral measures, including visual processing speed (hit latency) and reward retrieval, suggesting sustained effects on psychomotor function, motor coordination, and behavioral engagement that persisted for at least 4 hours after RORR. These findings support the utility of the rCPT as a translational paradigm for characterizing agent-specific and domain-specific trajectories of cognitive recovery following anesthesia.
- Open Access
- 17 August 2026
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 54 (9)
Pharmacokinetics of repeated, high-dose fentanyl administration in rats
- 17 August 2026
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 54 (9)
Open AccessPharmacokinetics of repeated, high-dose fentanyl administration in rats
- 6 July 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (3) , 662-666
Uncoupling immobility and unconsciousness
- 6 July 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (3) , 662-666
Uncoupling immobility and unconsciousness
- 9 September 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 143 (4) , 1049-1089
Current and Developing Approaches for Facilitating Emergence from General Anesthesia
Despite the widespread use of clinical anesthesia, the process of emergence from general anesthesia remains primarily driven by anesthetic elimination. Although emergence from general anesthesia is typically safe, prolonged delays strain resource-intensive settings and contribute to increased healthcare costs. In addition to improving access to care, providing clinicians with more precise control over emergence could offer diagnostic potential and improve patient outcomes. For decades, this unmet need has motivated research into the mechanisms underlying anesthetic emergence. Now, the first agents for facilitating emergence are entering the market, with more in development. This narrative review critically evaluates advancements in the development of emergence-promoting therapies, examining insights from preclinical research to clinical trials. This study categorizes prospective emergence agents/strategies into one of three primary approaches: (1) strategies that primarily manipulate anesthetic pharmacokinetics, (2) agents designed to directly target anesthetic receptor–binding sites, and (3) strategies that leverage arousal-promoting neural pathways. The parallel development of these approaches, each with their distinct strengths and limitations, holds promise for paving the way for a tailored approach to facilitate emergence.
- 9 September 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 143 (4) , 1049-1089
Current and Developing Approaches for Facilitating Emergence from General Anesthesia
Despite the widespread use of clinical anesthesia, the process of emergence from general anesthesia remains primarily driven by anesthetic elimination. Although emergence from general anesthesia is typically safe, prolonged delays strain resource-intensive settings and contribute to increased healthcare costs. In addition to improving access to care, providing clinicians with more precise control over emergence could offer diagnostic potential and improve patient outcomes. For decades, this unmet need has motivated research into the mechanisms underlying anesthetic emergence. Now, the first agents for facilitating emergence are entering the market, with more in development. This narrative review critically evaluates advancements in the development of emergence-promoting therapies, examining insights from preclinical research to clinical trials. This study categorizes prospective emergence agents/strategies into one of three primary approaches: (1) strategies that primarily manipulate anesthetic pharmacokinetics, (2) agents designed to directly target anesthetic receptor–binding sites, and (3) strategies that leverage arousal-promoting neural pathways. The parallel development of these approaches, each with their distinct strengths and limitations, holds promise for paving the way for a tailored approach to facilitate emergence.
- 21 August 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 135 (4) , 953-964
Drug-specific recovery of long-term memory and visual discrimination after anaesthetic-induced unconsciousness in rats
- 21 August 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 135 (4) , 953-964
Drug-specific recovery of long-term memory and visual discrimination after anaesthetic-induced unconsciousness in rats
- 12 June 2025
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 142 (3) , 455-464
Pharmacologic Reversal of Xylazine-Induced Unconsciousness in Rats
BACKGROUND: Xylazine is an alpha-2 adrenergic agonist approved for veterinary use as a sedative and analgesic for animals. Unfortunately, xylazine has recently become a common adulterant of street drugs in the United States with xylazine-related overdoses and deaths increasing each year. Although the alpha-2 adrenergic antagonist, atipamezole, is an efficacious reversal agent for xylazine that is approved for use in animals, it is not approved for humans. In this study, we aimed to test alternative reversal agents for xylazine, and compare them with atipamezole in a rat model of xylazine-induced unconsciousness. METHODS: In adult Sprague-Dawley rats, we induced loss of righting reflex (LORR, a surrogate end point for loss of consciousness) with xylazine (5 mg/kg, intravenous [IV]) and attempted to restore consciousness by administering agents with distinct molecular mechanisms of action: atipamezole (alpha-2 adrenergic antagonist, 200 µg/kg IV); d-amphetamine (norepinephrine and dopamine reuptake inhibitor and releasing agent, 1 mg/kg); chloro-APB (dopamine D1 receptor agonist, 3 mg/kg IV); and atomoxetine (norepinephrine reuptake inhibitor, 3 mg/kg IV). Pulse oximetry and heart rate were monitored continuously. After administration of the reversal agents, time to return of righting reflex (RORR) was recorded (n = 12) and animals were assessed with a novel object recognition test (n = 17). One subset of animals underwent surgery to have electroencephalogram (EEG) leads implanted (n = 4). EEG data were recorded after xylazine injection and ensuing administration of a reversal agent and spectral analysis was performed. RESULTS: After xylazine-induced unconsciousness, the median time to RORR in atipamezole-, d-amphetamine-, and chloro-APB-treated rats was 1.5 minutes (Interquartile Range [1.0–2.0]), 2 minutes (interquartile range [IQR] [1.0–3.0]), and 2 minutes (IQR [1.0–2.0]) post drug injection, respectively, compared to 56 minutes (IQR [39.5–70.5]) after saline control ( F [4,40] = 41.62, P < .0001). Atomoxetine did not significantly accelerate time to RORR. During the novel object recognition test, all animals spent the same amount of time with the familiar and novel object (range 0–143.5 sec), indicating that no reversal agents restored recognition memory. Xylazine induced an EEG pattern dominated by slow-delta oscillations. Atipamezole, d-amphetamine, and chloro-APB restored EEG oscillations similar to the awake state. CONCLUSIONS: Atipamezole, d-amphetamine, and chloro-APB accelerate emergence from xylazine-induced unconsciousness and restore EEG oscillation patterns consistent with wakefulness. However, none of these reversal agents restore recognition memory.
- 12 June 2025
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 142 (3) , 455-464
Pharmacologic Reversal of Xylazine-Induced Unconsciousness in Rats
BACKGROUND: Xylazine is an alpha-2 adrenergic agonist approved for veterinary use as a sedative and analgesic for animals. Unfortunately, xylazine has recently become a common adulterant of street drugs in the United States with xylazine-related overdoses and deaths increasing each year. Although the alpha-2 adrenergic antagonist, atipamezole, is an efficacious reversal agent for xylazine that is approved for use in animals, it is not approved for humans. In this study, we aimed to test alternative reversal agents for xylazine, and compare them with atipamezole in a rat model of xylazine-induced unconsciousness. METHODS: In adult Sprague-Dawley rats, we induced loss of righting reflex (LORR, a surrogate end point for loss of consciousness) with xylazine (5 mg/kg, intravenous [IV]) and attempted to restore consciousness by administering agents with distinct molecular mechanisms of action: atipamezole (alpha-2 adrenergic antagonist, 200 µg/kg IV); d-amphetamine (norepinephrine and dopamine reuptake inhibitor and releasing agent, 1 mg/kg); chloro-APB (dopamine D1 receptor agonist, 3 mg/kg IV); and atomoxetine (norepinephrine reuptake inhibitor, 3 mg/kg IV). Pulse oximetry and heart rate were monitored continuously. After administration of the reversal agents, time to return of righting reflex (RORR) was recorded (n = 12) and animals were assessed with a novel object recognition test (n = 17). One subset of animals underwent surgery to have electroencephalogram (EEG) leads implanted (n = 4). EEG data were recorded after xylazine injection and ensuing administration of a reversal agent and spectral analysis was performed. RESULTS: After xylazine-induced unconsciousness, the median time to RORR in atipamezole-, d-amphetamine-, and chloro-APB-treated rats was 1.5 minutes (Interquartile Range [1.0–2.0]), 2 minutes (interquartile range [IQR] [1.0–3.0]), and 2 minutes (IQR [1.0–2.0]) post drug injection, respectively, compared to 56 minutes (IQR [39.5–70.5]) after saline control ( F [4,40] = 41.62, P < .0001). Atomoxetine did not significantly accelerate time to RORR. During the novel object recognition test, all animals spent the same amount of time with the familiar and novel object (range 0–143.5 sec), indicating that no reversal agents restored recognition memory. Xylazine induced an EEG pattern dominated by slow-delta oscillations. Atipamezole, d-amphetamine, and chloro-APB restored EEG oscillations similar to the awake state. CONCLUSIONS: Atipamezole, d-amphetamine, and chloro-APB accelerate emergence from xylazine-induced unconsciousness and restore EEG oscillation patterns consistent with wakefulness. However, none of these reversal agents restore recognition memory.
- 19 December 2024
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 142 (3) , 465-475
Repeated High-dose Fentanyl Administration in Rats Reveals Minimal Tolerance to Unconsciousness, Bradycardia, Muscle Rigidity, and Respiratory Depression
Background: Fentanyl is a synthetic opioid that is widely used in anesthesiology, but its illicit use is rapidly increasing. At high doses, fentanyl induces unconsciousness and muscle rigidity, the mechanisms of which are poorly understood. Since animal models are needed to study these effects, the aim of this study was to establish a rat model of fentanyl abuse and investigate the effects of repeated high-dose fentanyl injections on loss of righting reflex, heart rate, respiratory depression, muscle, and brain activity. Methods: Male and female Sprague–Dawley rats were studied (n = 40). A bolus of 100 µg/kg fentanyl was administered intravenously twice a week for 5 consecutive weeks. Time to return of righting reflex after fentanyl injection and changes in electromyography/electroencephalography activity as well as heart rate were analyzed. Additionally, arterial blood gas analysis for evaluation of ventilation was performed. Mixed-effect models with Dunnett test and effect sizes were used for statistical analysis. Results: Repeated injections resulted in a U-shaped change in time to return of righting reflex with the longest latency after the first exposure (median, 50 [first to third quartile, 36 to 56] min) and the shortest after the fifth exposure (16 [13 to 33] min). After fentanyl administration, heart rate dropped immediately by 225 beats/min (95% CI, 179 to 271; F = 3,952.16; P < 0.001), while electromyography activity increased by 291% (95% CI, 212 to 370; F = 27.51; P < 0.001) and partial pressure of arterial carbon dioxide increased by 49.4 mmHg (95% CI, 40.6 to 58.2; F = 75.97; P < 0.001) within 5 min after injection. Additionally, pH decreased by 0.48 (95% CI, 0.41 to 0.54; F = 142.00; P < 0.01), and partial pressure of arterial oxygen decreased by 50.4 mmHg (40.8 to 60.0; F = 57.90; P < 0.001). Repeated fentanyl exposures did not significantly affect the extent of these changes (EMG, F = 1.63, P = 0.237; partial pressure of arterial carbon dioxide, F = 1.23, P = 0.312; heart rate, F = 1.05, P = 0.400; pH, F = 3.05, P = 0.066; arterial partial pressure of oxygen, F = 3.35, P = 0.052). Electroencephalography analysis revealed that repeated fentanyl exposures elicited significantly higher absolute power in frequencies greater than 20 Hz as indicated by an area under the receiver operator characteristics curve greater than 0.7. Conclusions: The authors established a rodent model of repeated high-dose fentanyl administration. Overall, significant evidence of tolerance was not observed after 10 exposures of high-dose fentanyl for any of the analyzed parameters. These results suggest that tolerance does not develop for fentanyl-induced unconsciousness, muscle rigidity, or respiratory depression.
- 19 December 2024
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 142 (3) , 465-475
Repeated High-dose Fentanyl Administration in Rats Reveals Minimal Tolerance to Unconsciousness, Bradycardia, Muscle Rigidity, and Respiratory Depression
Background: Fentanyl is a synthetic opioid that is widely used in anesthesiology, but its illicit use is rapidly increasing. At high doses, fentanyl induces unconsciousness and muscle rigidity, the mechanisms of which are poorly understood. Since animal models are needed to study these effects, the aim of this study was to establish a rat model of fentanyl abuse and investigate the effects of repeated high-dose fentanyl injections on loss of righting reflex, heart rate, respiratory depression, muscle, and brain activity. Methods: Male and female Sprague–Dawley rats were studied (n = 40). A bolus of 100 µg/kg fentanyl was administered intravenously twice a week for 5 consecutive weeks. Time to return of righting reflex after fentanyl injection and changes in electromyography/electroencephalography activity as well as heart rate were analyzed. Additionally, arterial blood gas analysis for evaluation of ventilation was performed. Mixed-effect models with Dunnett test and effect sizes were used for statistical analysis. Results: Repeated injections resulted in a U-shaped change in time to return of righting reflex with the longest latency after the first exposure (median, 50 [first to third quartile, 36 to 56] min) and the shortest after the fifth exposure (16 [13 to 33] min). After fentanyl administration, heart rate dropped immediately by 225 beats/min (95% CI, 179 to 271; F = 3,952.16; P < 0.001), while electromyography activity increased by 291% (95% CI, 212 to 370; F = 27.51; P < 0.001) and partial pressure of arterial carbon dioxide increased by 49.4 mmHg (95% CI, 40.6 to 58.2; F = 75.97; P < 0.001) within 5 min after injection. Additionally, pH decreased by 0.48 (95% CI, 0.41 to 0.54; F = 142.00; P < 0.01), and partial pressure of arterial oxygen decreased by 50.4 mmHg (40.8 to 60.0; F = 57.90; P < 0.001). Repeated fentanyl exposures did not significantly affect the extent of these changes (EMG, F = 1.63, P = 0.237; partial pressure of arterial carbon dioxide, F = 1.23, P = 0.312; heart rate, F = 1.05, P = 0.400; pH, F = 3.05, P = 0.066; arterial partial pressure of oxygen, F = 3.35, P = 0.052). Electroencephalography analysis revealed that repeated fentanyl exposures elicited significantly higher absolute power in frequencies greater than 20 Hz as indicated by an area under the receiver operator characteristics curve greater than 0.7. Conclusions: The authors established a rodent model of repeated high-dose fentanyl administration. Overall, significant evidence of tolerance was not observed after 10 exposures of high-dose fentanyl for any of the analyzed parameters. These results suggest that tolerance does not develop for fentanyl-induced unconsciousness, muscle rigidity, or respiratory depression.
- Open Access
- 3 July 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 133 (4) , 793-803
Dopaminergic psychostimulants cause arousal from isoflurane-induced sedation without reversing memory impairment in rats
- 3 July 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 133 (4) , 793-803
Open AccessDopaminergic psychostimulants cause arousal from isoflurane-induced sedation without reversing memory impairment in rats
- Open Access
- 29 May 2024
- Published by Elsevier in Brain Stimulation
- Vol. 17 (3) , 687-697
Electrical stimulation of the ventral tegmental area restores consciousness from sevoflurane-, dexmedetomidine-, and fentanyl-induced unconsciousness in rats
- 29 May 2024
- Published by Elsevier in Brain Stimulation
- Vol. 17 (3) , 687-697
Open AccessElectrical stimulation of the ventral tegmental area restores consciousness from sevoflurane-, dexmedetomidine-, and fentanyl-induced unconsciousness in rats